The fact remains that reduced time and cost of repurposing drug candidates remains a prominent advantage. contributes to battle the disease by its anti-aging and anti-obesity effects. Since, rapamycin focuses on the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral medicines as its effectiveness is less likely to become dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 illness. approaches to drug finding. Since a drug candidate with potential for repurposing has already gone through the medical trial process and has been tested for toxicity, it is generally safe to use. However, the overall strategy requires time, funding, and knowledge of medical trials and medical pharmacology to support the use in individuals. Although drug repurposing is not a new method, it has become of mainstream interest due to its obvious advantage in the reduction of drug development time and cost. Also, you will find fewer numbers of parameters required for drug repurposing during medical tests than those required for a new chemical entity to pass through the tests. Furthermore, the existing validated information about those medicines including formulations, dosing, toxicities, mechanism of actions, pharmacokinetics, and pharmacodynamics help in reducing or bypassing the methods in preclinical and early medical development . Therefore, through drug repurposing, a potential drug molecule incurs smaller cost and may directly Neoandrographolide enter the phase-2 of medical tests. This compares to traditional drug discovery where phase-1 medical trials must 1st become conducted to address the security, dosing, and toxicity profiles. That is not to say design SMOC1 and development of fresh drug molecules are less important; however, for a new drug molecule, the process to pass through medical trials can take 10C15 years and requires an expense of around $1 billion to reach the point of regulatory authorization. Neoandrographolide Often many of the medicines by no means make it to that stage. In contrast, repurposing of a drug molecule can be done inside a timespan of 2C6 years and only requires an expense approximating between US$ 0.2C0.3 billion. The overall success rate of repurposed medicines is similar to that of medicines developed through the route. Thus, it is the lack of drug efficacy that remains the primary reason for attrition during medical trials, actually for the repurposed medicines. Furthermore, if the repurposed medicines require different exposure routes than those used and authorized originally, then pharmacokinetic and toxicology studies will also be required. The fact remains that reduced time and cost of repurposing drug candidates remains a prominent advantage. Additionally, since these medicines were already proven to be sufficiently safe, they may be less likely to fail security tests when utilized for a different indicator. The current COVID-19 pandemic is definitely caused by SARS coronavirus-2 (SARS-CoV-2), which is an enveloped positive-sense, single-stranded RNA computer virus similar to the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) viruses . SARS and MERS led outbreaks are well known globally for his or her severe illness and lack of effective restorative medicines, which led to high morbidity and mortality rates. For the prevention or treatment of SARS-CoV-2 illness, there is no vaccine or drug at the present time. Antiviral providers designed in the future for the SARS-CoV-2 will target specific viral parts, but resistance to these medicines may develop due to multiple mutations in viral RNA, which leads to fresh viral variants. Consequently, therapeutics focusing on the host-cell machinery required for essential viral functions such as entry to sponsor cells, viral replication, assembly, and viral launch must be regarded as for future drug development. Due to the time and monetary expenses of developing a fresh drug through the process of drug finding, the drug repurposing represents a greatly useful and impactful avenue for cost-effective and timely treatment of COVID-19. Rapamycin for the treatment of COVID-19: Rapamycin is definitely a macrolide immunosuppressant that inhibits the mTOR. The mTOR is definitely a serine/threonine protein kinase that is present in the form of two protein Neoandrographolide complexes (mTORC1 and mTORC2) with unique protein parts and substrates.